Tausch, E. Ljungström, V. Agathangelidis, A. Zapatka, M. Scarfò, L. Jebaraj, B.M.C. Yosifov, D.Y. Müller, A. Munugalavadla, V. Degenhardt, J.D. Ghia, P. Rosenquist, R. Stilgenbauer, S., Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations, Blood advances, (139), 3340-3344, 2022, NLM (Medline),